Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance.

2区 医学 Q1 Medicine Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-04-07 DOI:10.1016/bs.acr.2023.03.002
Sandhik Nandi, Atanu Mondal, Aritra Ghosh, Shravanti Mukherjee, Chandrima Das
{"title":"Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance.","authors":"Sandhik Nandi,&nbsp;Atanu Mondal,&nbsp;Aritra Ghosh,&nbsp;Shravanti Mukherjee,&nbsp;Chandrima Das","doi":"10.1016/bs.acr.2023.03.002","DOIUrl":null,"url":null,"abstract":"<p><p>Long noncoding RNAs (lncRNAs) comprise a diverse class of RNA molecules that regulate various physiological processes and have been reported to be involved in several human pathologies ranging from neurodegenerative disease to cancer. Therapeutic resistance is a major hurdle for cancer treatment. Over the past decade, several studies has emerged on the role of lncRNAs in cancer drug resistance and many trials have been conducted employing them. LncRNAs also regulate different cell death pathways thereby maintaining a fine balance of cell survival and death. Autophagy is a complex cell-killing mechanism that has both cytoprotective and cytotoxic roles. Similarly, autophagy can lead to the induction of both chemosensitization and chemoresistance in cancer cells upon therapeutic intervention. Recently the role of lncRNAs in the regulation of autophagy has also surfaced. Thus, lncRNAs can be used in cancer therapeutics to alleviate the challenges of chemoresistance by targeting the autophagosomal axis. In this chapter, we discuss about the role of lncRNAs in autophagy-mediated cancer drug resistance and its implication in targeted cancer therapy.</p>","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"160 ","pages":"133-203"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acr.2023.03.002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Long noncoding RNAs (lncRNAs) comprise a diverse class of RNA molecules that regulate various physiological processes and have been reported to be involved in several human pathologies ranging from neurodegenerative disease to cancer. Therapeutic resistance is a major hurdle for cancer treatment. Over the past decade, several studies has emerged on the role of lncRNAs in cancer drug resistance and many trials have been conducted employing them. LncRNAs also regulate different cell death pathways thereby maintaining a fine balance of cell survival and death. Autophagy is a complex cell-killing mechanism that has both cytoprotective and cytotoxic roles. Similarly, autophagy can lead to the induction of both chemosensitization and chemoresistance in cancer cells upon therapeutic intervention. Recently the role of lncRNAs in the regulation of autophagy has also surfaced. Thus, lncRNAs can be used in cancer therapeutics to alleviate the challenges of chemoresistance by targeting the autophagosomal axis. In this chapter, we discuss about the role of lncRNAs in autophagy-mediated cancer drug resistance and its implication in targeted cancer therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Lnc-ing表观遗传机制与自噬和癌症耐药性。
长非编码RNA(lncRNA)包括一类不同的RNA分子,它们调节各种生理过程,并已被报道与从神经退行性疾病到癌症等多种人类病理有关。治疗耐药性是癌症治疗的主要障碍。在过去的十年里,已经出现了几项关于lncRNA在癌症耐药性中的作用的研究,并且已经进行了许多使用它们的试验。lncRNA还调节不同的细胞死亡途径,从而保持细胞存活和死亡的良好平衡。自噬是一种复杂的细胞杀伤机制,具有细胞保护和细胞毒性作用。类似地,自噬可以在治疗干预后诱导癌症细胞的化学增敏和化学耐药性。最近lncRNA在自噬调节中的作用也浮出水面。因此,lncRNA可用于癌症治疗,通过靶向自噬体轴来缓解化疗耐药性的挑战。在本章中,我们讨论了lncRNA在自噬介导的癌症耐药性中的作用及其在癌症靶向治疗中的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in Cancer Research
Advances in Cancer Research 医学-肿瘤学
CiteScore
10.00
自引率
0.00%
发文量
52
期刊介绍: Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. The first ACR volume came out in the year that Watson and Crick reported on the central dogma of biology, the DNA double helix. In the first 100 volumes are found many contributions by some of those who helped shape the revolution and who made many of the remarkable discoveries in cancer research that have developed from it.
期刊最新文献
Hereditary diffuse gastric cancer. Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach. Targeting the super elongation complex for oncogenic transcription driven tumor malignancies: Progress in structure, mechanisms and small molecular inhibitor discovery. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors. Collaborative Spirit Drives the Field of Tumor Glycobiology: A Preface to Special Volume on Cancer Glycobiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1